Critically examine how global commodity price shocks can undermine India's essential-drug price control regime, with reference to the recent cisplatin-carboplatin shortage.

The Drugs (Prices Control) Order (DPCO), 2013 empowers the NPPA to cap prices of essential formulations to protect affordability [1]. The 2026 cisplatin–carboplatin shortage shows how an external input-cost shock can convert that affordability into unavailability — exposing the regime's rigidity without negating its worth.

How the shock transmitted

• Platinum, the raw material for both drugs, saw prices more than double globally; India imports it, notably from South Africa [5].
• Disrupted West Asia shipping routes raised freight costs and restricted raw-material arrivals [5].
• Old ceiling rates (cisplatin ₹7.26/ml, carboplatin ₹60.49/ml) turned production financially unviable, halting manufacturing lines [5].
• Result: disrupted chemotherapy cycles for ovarian, lung, head-and-neck and testicular cancers, with private hospitals worse hit than government ones [5].

Where the regime proved brittle

• Ceiling revisions are periodic and index-linked, too slow to track a sudden commodity spike; there is no automatic input-cost pass-through.
• Import dependence for APIs and critical minerals remains structural — the Department of Pharmaceuticals itself flags APIs where Chinese imports exceed 70% of the total [3].
• No shortage early-warning or buffer-stocking mechanism for life-saving oncology drugs.
• Uneven outcomes across public and private facilities raise equity concerns in cancer care.

Yet the regime showed adaptive capacity

• Paragraph 19, DPCO allows extraordinary, public-interest price fixation [1]; invoking it, the Centre approved a one-time 50% hike (cisplatin ₹10.89/ml; carboplatin ₹90.74/ml), reviewable in six months — restoring supply without permanent price escalation [5].
• Comparable 50% revisions for scheduled drugs have earlier been used precisely to balance availability with affordability [2].

Price control is therefore not the disease but an instrument needing better shock-absorbers. An automatic input-cost trigger, essential-drug stockpiles, and deeper API and mineral self-reliance through PLI for bulk drugs and Bulk Drug Parks [3], alongside market diversification for supply-chain resilience [4], can align cheap medicines with dependable ones — the true test of the right to health under Article 21.